Est Establishment Labs Holdings Inc. announced both the two-year clinical results of Mia Femtech as well as its launch of Zen, the Company's next generation RFID technology, at the 8th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Lisbon, Portugal. The Mia Feasibility Clinical Study is an IRB-approved prospective study that enrolled 100 subjects between December 2020 and April 2021. There were also no reports of bleeding, hematoma, or seroma requiring intervention in the study.

The follow-up compliance rate at two years was 90%. In addition to announcing the Mia study data, Establishment Labs is also launching Zen, which is part of its next generation Zensor RFID platform. All Motiva implants are available with a passive RFID technology, known as Qid, that provides direct access to device identification information for full compliance as well as for patient peace of mind.

Since Qid became available in 2014, approximately two million devices with the technology have been placed in market. The new Zen technology has all the previous benefits of Qid, but is now entirely non-ferromagnetic. Motiva Ergonomix2 Diamond implants used in the Mia Femtech system feature Zen, and it will initially be available in select geographies with Motiva Ergonomix 2 Round implants in the Joy program.

Zen with temperature sensing is currently in human trials as part of an IRB-approved study. The World Symposium on Ergonomix2 Diamond implantable Implants is being held October 13-14 in Lisbon, Portugal. All data presented is preliminary two-year follow-up data and does not reflect the final study results nor establish the ultimate safety or effectiveness of the procedure.